Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 139

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 139
---
 the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and
U.S. medical practice and (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations. Additionally, the FDA’s clinical trial requirements, including sufficient size of

86

patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop being delayed or not receiving approval for commercialization in the applicable jurisdiction. Risks Related to Ownership of our Common Stock The market price of our Common Stock may fluctuate significantly, and investors in our Common Stock may lose all or a part of their investment. The market prices for securities of biotechnology and pharmaceutical companies have historically been highly volatile, and the market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. For example, from November 11, 2022 (the first trading day following the closing of the Scilex Business Combination) to December 5, 2025, our closing stock price ranged from $3.99 to $518.03. The market price of our Common Stock may fluctuate significantly in response to numerous factors, some of which are beyond our control, such as:

| • |     | our ability to commercialize ZTlido, GLOPERBA, ELYXYB or our product candidates, if approved; |

| • |     | legal disputes or other developments relating to proprietary rights, including patents, litigation matters and                                                                                                                             
 our ability to obtain patent protection for ZTlido, GLOPERBA, ELYXYB or our product candidates, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation; |

| • |     | announcements of the introduction of new products by our company and our competitors; |

| • |     | issuances of debt or equity securities; |

| • |     | market conditions and trends in